Scientists compare risk of two medications for type 2 diabetes
Research published in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes
has revealed that the risk of heart disease and death were similar for type 2 diabetes patients who took either rosiglitazone or pioglitazone.
Scientists evaluated over 36,000 patients who had taken one of the two drugs over a period of 33 months. They adjusted the data based on age, gender, prior heart diseases and diabetes-related complications.
The team found that 602 patients taking rosiglitazone died from a heart attack or heart failure compared to 599 individuals who had taken pioglitazone.
"This study provides patients and their doctors with another source of information about rosiglitazone and pioglitazone - sold as Avandia and Actos, respectively - as they determine the best therapy for diabetes patients," said lead investigator Debra Wertz of HealthCore.
These findings contradicted the results of earlier studies, which suggested that rosiglitazone induced a greater risk of heart attack. The Food and Drug Administration decided to keep the drug on the market this year due to its benefits outweighing its risks, but they have added additional warnings and restrictions.